Published online Aug 16, 2024. doi: 10.4253/wjge.v16.i8.451
Revised: July 6, 2024
Accepted: July 16, 2024
Published online: August 16, 2024
Processing time: 47 Days and 9.6 Hours
Malignant gastric outlet obstruction (mGOO) is a major condition affecting patients with periampullary tumors, including pancreatic cancer. The current treatment options include surgical gastroenterostomy, endoscopic stenting and more recently EUS-guided gastroenterostomy. Most studies comparing the outcomes of the three procedures focus on technical success, clinical success and safety. Several “occult” outcomes relevant to the patient’s viewpoints and perspective may ultimately impact on cancer-related and overall survival, such as body mass composition, nutritional biomarkers, chemotherapy tolerance and patient-reported quality of life. The aim of this review is to provide an overview of potential key outcomes that should be explored in future comparative research around mGOO treatment options.
Core Tip: Gastric outlet obstruction (GOO) is a common complication in pancreatobiliary malignancies, with growing research on its surgical and endoscopic management. However, current studies often overlook the patient's perspective and important clinical outcomes. This publication discusses the need to incorporate body mass composition, nutritional status, chemotherapy tolerance, and quality of life into future GOO research to provide a more comprehensive understanding of patient well-being and treatment effectiveness.